GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
C/NL/06/01_001 Suntory Flowers Limited Application for renewal of consent for marketing approval under Directive 2001/18/EC (Event FLORIGENE®Moonaqua™(FLO-4Ø689-6)) 09-11-2018 Vergunning verleend
C/NL/13/02/00 Suntory Holdings Application to import cut-flowers of carnation (Dianthus caryophyllus) line FLO-40685-2 for distribution and retail under directive 2001/18/EC 05-09-2019 Vergunning verleend
IM-L 19-001_000 Photanol Productie van organisch zuur met cyanobacteriën Ontwerpbesluit genomen
IM-MV 19-006_000 Prinses Máxima Centrum Clinical testing of Lenti-D Drug Product, an autologous CD34+ cell-enriched population that contains cells transduced with lentiviral vector (LVV) that encodes an ABCD1 complementary DNA (cDNA) for human adrenoleukodystrophy protein (ALDP) Ontwerpbesluit genomen
IM-MV 19-008_000 Het Nederlands Kanker Instituut Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers 01-10-2019 Vergunning verleend
IM-MV 19-009_000 Erasmus MC A Phase III, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Patients with Malignant Pleural Mesothelioma Vergunning verleend
IM-MV 19-014_000 UMCG Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells 26-09-2019 Vergunning verleend
IM-MV 19-015_000 VU medisch centrum Clinical trials testing bb2121, consisting of autologous T lymphocytes ex-vivo transduced by a replication-defective lentiviral vector to express anti-BCMA chimeric antigen receptors (CAR) to target tumor cells expressing the human B cell maturation antigen (BCMA), in patients with multiple myeloma 17-10-2019 Vergunning verleend
IM-MV 19-016_000 Erasmus MC Gene therapy clinical development program (CDP) comprising clinical trials using the advanced therapy medicinal product (ATMP) SPK-3006, a recombinant adeno-associated viral (AAV) vector with a bioengineered capsid and a codon-optimized expression cassette encoding a secretable human acid alpha glucosidase (GAA) gene for gene transfer in individuals with Pompe disease Ontwerpbesluit genomen
IM-MV 19-017_000 Universitair Medisch Centrum Utrecht Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers 17-10-2019 Vergunning verleend
IM-MV 19-019_000 Erasmus MC Testing the safety and efficacy of JCAR017 in patients with aggressive B cell malignancies Ontwerpbesluit genomen
IM-MV 19-020_000 Stichting Katholieke Universiteit A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) Ontwerpbesluit genomen
IM-MV 19-021_000 Erasmus MC Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers Ontwerpbesluit genomen
IM-MV 19-023_000 UMCG Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-specific (c259) T cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO and/or LAGE-1a Positive Cancers Ontwerpbesluit genomen